Steroid-Reducing Options For ReLapsING PMR (STERLING-PMR): A Pragmatic, Randomised Trial To Compare The Clinical And Cost-effectiveness Of Adding Immunosuppression To Steroid-tapering Treatment For Patients With Relapsing PMR, Versus Steroid-tapering
Funder
National Health and Medical Research Council
Funding Amount
$823,722.00
Summary
Polymyalgia rheumatica (PMR) is a common inflammatory disease of older people, treated with prednisolone (steroid tablet). About 50% will relapse and often suffer from steroid side effects (eg diabetes, bone fracture). This study will determine whether an extra treatment can reduce prednisolone use in people with relapsing PMR; and improve quality of life. The study will include participants in UK and Australia and provide a unique opportunity for further research in this under-researched area.
HMGB1: A Novel Player In The Pathogenesis Of Inflammatory Myositis?
Funder
National Health and Medical Research Council
Funding Amount
$84,800.00
Summary
The project aims to determine whether HMGB1, a pro-inflammatory molecule, plays a key role in the cause of inflammatory myositis, an extremely disabling muscle condition characterised by progressive weakness.
Citrullination In Rheumatic And Non-rheumatic Diseases
Funder
National Health and Medical Research Council
Funding Amount
$89,699.00
Summary
Rheumatoid arthritis is a common condition affecting about 1% of the population, leading to damage of joints and subsequently impaired function. This damage is caused by an immune system which rather than defending the host against threats such as infections, inadvertently attacks the host leading to joint damage. Ultimately a better understanding of the abnormal immune responses in patients with RA will allow us to more accurately the diagnose and manage this condition
Development Of A Preventive Strategy For Rheumatic Heart Disease Using An Experimental Model
Funder
National Health and Medical Research Council
Funding Amount
$370,846.00
Summary
Based on animal studies, we aim to demonstrate that the worsening of heart damage seen in patients with rheumatic heart disease (RHD) is due to repeated infections with bacteria (group A streptococci: GAS). The heart damage is caused by continual immune damage to the heart and valves and this has adverse effects on heart function. We will also investigate a novel way to prevent the development of RHD.
Group A streptococcal diseases, including rheumatic heart disease, are major causes of illness globally, mostly in developing countries. This proposal is an investigation into how best to tackle control these diseases. It focuses on 1) a novel way to detect rheumatic heart disease in its earliest phases using ultrasound, 2) using a single drug once per year to stop streptococcal skin sores by controlling scabies infestation in whole communities and 3) developing a new vaccine that is applicable ....Group A streptococcal diseases, including rheumatic heart disease, are major causes of illness globally, mostly in developing countries. This proposal is an investigation into how best to tackle control these diseases. It focuses on 1) a novel way to detect rheumatic heart disease in its earliest phases using ultrasound, 2) using a single drug once per year to stop streptococcal skin sores by controlling scabies infestation in whole communities and 3) developing a new vaccine that is applicable across all regions of the world.Read moreRead less
Developing A Safe Vaccine Against Group A Streptococci
Funder
National Health and Medical Research Council
Funding Amount
$768,530.00
Summary
Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified new protective candidate antigens, and we seek to undertake critical non-human primate studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Sanofi Pasteur) leading to human trials and the development of a safe group A streptococcal vaccine for human use.
Towards The Elimination Of Tuberculosis And Rheumatic Heart Disease In Northern Australia And Our Region
Funder
National Health and Medical Research Council
Funding Amount
$258,600.00
Summary
My research program addresses tuberculosis and rheumatic heart disease, which are leading challenges for Northern Australia and our region. Both are diseases caused by infections with long-term complications. They cause illness and death in young Aboriginal people and neighbouring Southeast Asian populations. There are many gaps in our ability to effectively detect and prevent these diseases. My research targets these gaps, from cutting-edge science to translation of guidelines into practice.
The END RHD CRE: Developing An Endgame For Rheumatic Heart Disease In Australia
Funder
National Health and Medical Research Council
Funding Amount
$2,601,147.00
Summary
Rheumatic heart disease (RHD) is caused by an abnormal immune reaction to some bacterial infections. Although RHD is rare in developed countries, Indigenous Australians still live with the burden of RHD. The END RHD CRE will explore risk factors for RHD, prevention with antibiotics, management of RHD and the potential for vaccine development. Individuals and communities experiencing RHD are integral partners to this work. The CRE will establish a strategy for ending RHD in Australia.
Translating Rheumatic Fever Prevention Strategies Into Practice In Australia's High Burden Settings
Funder
National Health and Medical Research Council
Funding Amount
$178,157.00
Summary
Rheumatic fever is a serious preventable disease causing premature illness and death, yet unacceptably high rates occur in Australian Indigenous communities. Prevention can be achieved with regular penicillin injections, but there are many barriers, so people needing this treatment frequently miss doses. This program proposes to close the evidence-practice gap by forming effective partnerships to effectively roll out rheumatic fever prevention strategies in clinics across the Northern Territory.